Harbor Capital Advisors Inc. Buys 23,947 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Harbor Capital Advisors Inc. grew its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 99.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,063 shares of the biopharmaceutical company’s stock after buying an additional 23,947 shares during the period. Harbor Capital Advisors Inc. owned 0.06% of Xenon Pharmaceuticals worth $1,892,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. lifted its holdings in Xenon Pharmaceuticals by 174.7% during the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 641 shares in the last quarter. nVerses Capital LLC purchased a new position in shares of Xenon Pharmaceuticals during the 3rd quarter valued at $102,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Xenon Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 487 shares in the last quarter. Quarry LP boosted its holdings in Xenon Pharmaceuticals by 207.7% in the 2nd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 2,700 shares during the period. Finally, EntryPoint Capital LLC purchased a new stake in Xenon Pharmaceuticals in the 1st quarter worth $195,000. 95.45% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals Stock Up 0.0 %

Shares of NASDAQ:XENE opened at $41.71 on Tuesday. The stock has a market capitalization of $3.16 billion, a P/E ratio of -15.22 and a beta of 1.25. Xenon Pharmaceuticals Inc. has a 52 week low of $27.99 and a 52 week high of $50.99. The firm has a fifty day simple moving average of $40.62 and a two-hundred day simple moving average of $40.16.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.05). During the same quarter in the prior year, the company posted ($0.72) EPS. On average, analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Needham & Company LLC lowered their price objective on Xenon Pharmaceuticals from $62.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, September 3rd. Raymond James reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. HC Wainwright started coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, October 1st. They issued a “buy” rating and a $53.00 target price on the stock. Finally, William Blair raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $57.45.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.